Clinical profile of cases of kala-azar in Bihar.
作者信息
Aikat B K, Sahaya S, Pathania A G, Bhattacharya P K, Desai N, Prasad L S, Mishra S, Jain S
出版信息
Indian J Med Res. 1979 Oct;70:563-70.
PMID:541003
Abstract
摘要
相似文献
1
Clinical profile of cases of kala-azar in Bihar.比哈尔邦黑热病病例的临床概况。
Indian J Med Res. 1979 Oct;70:563-70.
2
Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).比哈尔邦黑热病（包括黑热病后皮肤利什曼病）的流行病学、临床及治疗特征
Trans R Soc Trop Med Hyg. 1984;78(3):391-8. doi: 10.1016/0035-9203(84)90131-7.
3
Study of the outbreak of kala-azar epidemic in Bihar.比哈尔邦黑热病疫情爆发的研究。
J Assoc Physicians India. 1978 Jun;26(6):511-8.
4
Epidemiology of visceral leishmaniasis in India.印度内脏利什曼病的流行病学
Natl Med J India. 1999 Mar-Apr;12(2):62-8.
5
Clinical profile of kala-azar in north Bihar.比哈尔邦北部黑热病的临床概况
J Indian Med Assoc. 1986 Dec;84(12):367-9.
6
Kala-azar hits again.黑热病再次来袭。
J Trop Med Hyg. 1981 Dec;84(6):271-6.
7
Knowledge, attitude, and practices related to Kala-azar in a rural area of Bihar state, India.印度比哈尔邦一个农村地区与黑热病相关的知识、态度和行为
Am J Trop Med Hyg. 2006 Sep;75(3):505-8.
8
Recent trends in the incidence and epidemiology of Kala-azar in Madras city.马德拉斯市黑热病的发病率及流行病学的近期趋势。
J Commun Dis. 1988 Sep;20(3):185-95.
9
Clinicoepidemiological profile of kala azar patients in Delhi.
J Commun Dis. 1989 Dec;21(4):255-61.
10
Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.两性霉素B治疗黑热病对印度比哈尔邦皮肤利什曼病发病率的影响。
Indian J Med Res. 2008 Jul;128(1):38-44.
引用本文的文献
1
Effectiveness of Short-Course Meglumine Antimoniate (Glucantime®) for Treatment of Visceral Leishmaniasis: A 13-Year, Multistage, Non-Inferiority Study in Iran.短疗程葡甲胺锑酸盐（葡糖胺锑钠®）治疗内脏利什曼病的疗效：伊朗一项为期13年的多阶段非劣效性研究。
Am J Trop Med Hyg. 2017 Jan 11;96(1):182-189. doi: 10.4269/ajtmh.16-0345. Epub 2016 Nov 22.
2
The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities?到2010年消除黑热病（内脏利什曼病）的希望破灭，且该病在印度周期性爆发，这该归咎于病媒控制措施、与人类免疫缺陷病毒的共同感染还是治疗方式呢？
Trop Parasitol. 2014 Jan;4(1):10-9. doi: 10.4103/2229-5070.129143.
3
Use of antimony in the treatment of leishmaniasis: current status and future directions.锑在利什曼病治疗中的应用：现状与未来方向。
Mol Biol Int. 2011;2011:571242. doi: 10.4061/2011/571242. Epub 2011 Jun 8.
4
Drug resistance in leishmaniasis.利什曼病中的耐药性。
J Glob Infect Dis. 2010 May;2(2):167-76. doi: 10.4103/0974-777X.62887.
5
Drug resistance in leishmaniasis.利什曼病中的耐药性。
Clin Microbiol Rev. 2006 Jan;19(1):111-26. doi: 10.1128/CMR.19.1.111-126.2006.
6
Efficacy of amphotericin B in multi-drug resistant kala-azar in children in first decade of life.两性霉素B对10岁以下儿童耐多药黑热病的疗效。
Indian J Pediatr. 1993 Jan-Feb;60(1):29-36. doi: 10.1007/BF02860503.
7
Immune complexes in Indian kala-azar.印度黑热病中的免疫复合物。
Bull World Health Organ. 1982;60(6):945-50.
Zotero 插件